same as their interim results 89 |
4.879 |
Jump to 5.68 |
|
|
or death when given within three days of |
5.2 |
Jump to 10.559 |
|
|
symptoms to high-risk patients it was 88 |
4.48 |
Jump to 12.639 |
|
|
when given within five days which |
3.121 |
Jump to 15.759 |
|
|
versus 12 on placebo and these data are |
5.04 |
Jump to 22.96 |
|
|
the company also for the first time |
4.24 |
Jump to 37.36 |
|
|
alleviation of four straight days of |
4.48 |
Jump to 56.48 |
|
|
seventy percent also both studies showed |
5.92 |
Jump to 62.879 |
|
|
a tenfold decrease in viral load at five |
5.2 |
Jump to 65.68 |
|
|
merck's results go from about a 50 |
4.081 |
Jump to 87.119 |
|
|
death risk down to 30 percent in the |
3.919 |
Jump to 91.2 |
|
|
meeting was november 30th it was two |
3.44 |
Jump to 139.68 |
|
|
between the 89 number and the 70 number |
5.519 |
Jump to 163.44 |
|
|
yeah so there were two separate trials |
5.04 |
Jump to 169.04 |
|
|
the 89 number was in folks who have risk |
5.6 |
Jump to 171.12 |
|
|
trial the 70 that was folks who are |
4.881 |
Jump to 184.159 |
|
|
significant at 70 percent |
3.92 |
Jump to 199.2 |
|
|